Infliximab therapy for idiopathic retinal vasculitis, aneurysm, and neuroretinitis syndrome

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 4, 2011, Pages 407-410

  Cheema, Rizwan A ^a,c   Al Askar, Essam ^a   Cheema, Haider R ^b  

^a Dhahran Eye Specialist Hospital ^*  (Saudi Arabia)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; MYCOPHENOLIC ACID; PREDNISOLONE;

ADULT; ANEURYSM; ARTERIOLE; ARTICLE; BLURRED VISION; CASE REPORT; DETERIORATION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EYE DISEASE; EYE EXAMINATION; EYE FUNDUS; EYE INFLAMMATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; HYPEREMIA; IDIOPATHIC RETINAL VASCULITIS, ANEURYSM, AND NEURORETINITIS SYNDROME; INFLAMMATORY CELL; LASER COAGULATION; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; OPTIC DISK; OPTIC NERVE; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; RHEUMATOLOGY; SCLEROSIS; SINGLE DRUG DOSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VITREOUS FLOATERS; VITREOUS HEMORRHAGE;

EID: 79961206507     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2010.0189     Document Type: Article

References (8)

1. Chang, T.S., Aylward, G.W., Davis, J.L., Mieler, W.F., Oliver, G.L., Maberley, A.L., and Gass, J.D. Idiopathic retinal vasculitis, aneurysms, and neuro-retinitis. Retinal vasculitis study. Ophthalmology 102:1089-1097, 1995.
2. Samuel, M.A., Equi, R.A., Chang, T.S., Mieler, W., Jampol, L.M., Hay, D., and Yannuzzi, L.A. Idiopathic retinitis, vasculitis, aneurysms, and neuroretinitis (IRVAN): New observations and a proposed staging system. Ophthalmology 114:1526-1529, 2007.
3. Karagiannis, D., Soumplis, V., Georgalas, I., and Kandarakis, A. Ranibizumab for idiopathic retinal vasculitis, aneurysms, and neuroretinitis: Favorable results. Eur. J. Ophthalmol. 20:792-794, 2009.
4. Dick, A.D., Forrester, J.V., Liversidge, J., and Cope, A.P. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog. Retin. Eye. Res. 23:617-637, 2004. (Pubitemid 39243969)
5. Sharma, S.M., Nestel, A.R., Lee, R.W., and Dick, A.D. Clinical review: Anti-TNFalpha therapies in uveitis: Perspective on 5 years of clinical experience. Ocul. Immunol. Inflamm. 17:403-414, 2009.
6. Lee, R.W., and Dick, A.D. Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Behçet's uveitis. Br. J. Ophthalmol. 94:269-270, 2010.
7. Yamada, Y., Sugita, S., Tanaka, H., Kamoi, K., Kawaguchi, T., and Mochizuki, M. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br. J. Ophthalmol. 94:284-288, 2010.
8. Keane, J., Gershon, S., Wise, R.P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W.D., Siegel, J.N., and Braun, M.M. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345:1098-1104, 2001.